✦ LIBER ✦

Albumin IFN-α fusion protein reduces viral load in HCV

Book ID: 120855002
Publisher: Adis International Limited (now part of Wolters Kluwer Health)
Year: 2005
Weight: 120 KB
Volume: &NA;
Category: Article
ISSN: 1173-8324
DOI: 10.2165/00128413-200514840-00012

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PEG IFN-α-2a + ribavirin reduces viral l

PEG IFN-α-2a + ribavirin reduces viral load in HCV infections

📂 Article 📅 2005 🏛 Adis International Limited (now part of Wolters Kl ⚖ 139 KB

Valopicitabine + peginterferon-α-2b redu

Valopicitabine + peginterferon-α-2b reduces viral load in HCV

📂 Article 📅 2005 🏛 Adis International Limited (now part of Wolters Kl ⚖ 133 KB

416 CONSERVED PEPTIDES REDUCE VIRAL LOAD

416 CONSERVED PEPTIDES REDUCE VIRAL LOADS IN CHRONIC PATIENTS INFECTED WITH HCV GENOTYPE 4 WHO DID NOT RESPOND TO IFN/RBV TREATMENT

✍ M.K. ElAwady; M.A. El Guindy; A.R. Zayadi; K. Atef; R. El Shenawy; N.G. Badr El 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 42 KB

The cyclophilin inhibitor Debio 025 comb

The cyclophilin inhibitor Debio 025 combined with PEG IFNα2a significantly reduces viral load in treatment-naïve hepatitis C patients

✍ Robert Flisiak; Saya V. Feinman; Maciej Jablkowski; Andrzej Horban; Wieslaw Kryc 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 727 KB

The anti-hepatitis C virus (HCV) effect and safety of three different oral doses of the cyclophilin inhibitor Debio 025 in combination with pegylated interferon-␣2a (PEG IFN-␣2a) were investigated in a multicenter, randomized, double-blind, placebo-controlled escalating dose-ranging phase II study i

O.079 Novel sustained release formulatio

O.079 Novel sustained release formulation of IFN α-2b improves tolerability and demonstrates potent viral load reduction in a phase I/II HCV clinical trial

✍ C. Trépo; R. Meyrueix; M. Maynard; R. Rouzier; M. Bourliere; Y. Donazzolo; J. Za 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 129 KB